杭州嘉因生物科技

Jiayin Biotech is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of next-generation gene therapies. The company leverages its proprietary adeno-associated virus (AAV) platform to target rare diseases, neuromuscular disorders, and ophthalmic conditions. Its lead candidate, EXG001-034, is a gene therapy for Spinal Muscular Atrophy (SMA) currently in clinical development. Jiayin Biotech also advances programs for wet age-related macular degeneration and hemophilia. The company maintains integrated capabilities spanning R&D, clinical development, and GMP manufacturing. Supported by prominent investors like Hillhouse and Lilly Asia Ventures, Jiayin Biotech aims to provide curative treatments for patients with high unmet medical needs.